comparemela.com

Apnea Participants During News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Axsome to Present New Sunosi Data at SLEEP 2023

Axsome Therapeutics Inc will present new data on Sunosi (solriamfetol) at SLEEP 2023, including results from the SHARP study.

United kingdomRussell rosenbergHans van dongenJohannes gutenbergDepartment of neurologyAxsome therapeutics incNeurotrials researchProfessor at washington state universityMedicine centerWashington state universityDrug administrationCognitive healthApnea participants duringRandomized placebo controlledObstructive sleep apneaExcessive daytime

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apneaNEW YORK, June 01, 2023 Axsome Therapeutics, Inc. , a. | June 1, 2023

United kingdomUnited statesNew yorkDarren oplandHans van dongenJohannes gutenbergMark jacobsonRussell rosenbergResearch societyWorld trade centerDrug administrationNeurotrials researchCorporate communicationsProfessor at washington state universityUs drug enforcement agency onSk biopharmaceuticals co ltd

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with. | May 30, 2023

United statesNew yorkGregory mattinglyRakesh jainEileen learyAndrew cutlerSamantha floamDarren oplandZachariah thomasMark jacobsonClinical professor of psychiatry at washington universityAxsome therapeutics incMd texas tech university school of medicineWorld trade centerNational survey on drugSk biopharmaceuticals co ltd

Axsome Presents New Data for Solriamfetol in SHARP Study

Axsome is sharing data from a study of solriamfetol in 59 patients with EDS associated with OSA and impaired cognitive function.

United statesUnited kingdomHans van dongenDrug administrationAmerican academy of neurologyUs drug enforcement agency onProfessor at washington state universityAxsome therapeuticsCognitive healthApnea participants duringRandomized placebo controlledAnnual meetingBritish columbia cognitive complaints inventoryEpworth sleepinessWashington state universityEnforcement agency

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

NEW YORK, April 21, 2023 Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today. | April 21, 2023

United statesUnited kingdomNew yorkMark jacobsonStuartj tepperAxsome moDarren oplandEileen learyZachariah thomasSamantha floamHans van dongenSk biopharmaceuticals co ltdAffairs at axsomeClinical development at axsomeAxsome therapeutics incGeisel school of medicine at dartmouth

vimarsana © 2020. All Rights Reserved.